The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Open accessAbstract
Favipiravir has been developed as an anti-influenza drug and licensed as an anti-influenza drug in Japan. Additionally, favipiravir is being stockpiled for 2 million people as a countermeasure for novel influenza strains. This drug functions as a chain terminator at the site of incorporation of the viral RNA and reduces the viral load. Favipiravir cures all mice in a lethal influenza infection model, while oseltamivir fails to cure the animals. Thus, favipiravir contributes to curing animals with lethal infection. In addition to influenza, favipiravir has a broad spectrum of anti-RNA virus activities in vitro and efficacies in animal models with lethal RNA viruses and has been used for treatment of human infection with life-threatening Ebola virus, Lassa virus, rabies, and severe fever with thrombocytopenia syndrome. The best feature of favipiravir as an antiviral agent is the apparent lack of generation of favipiravir-resistant viruses. Favipiravir alone maintains its therapeutic efficacy from the first to the last patient in an influenza pandemic or an epidemic lethal RNA virus infection. Favipiravir is expected to be an important therapeutic agent for severe influenza, the next pandemic influenza strain, and other severe RNA virus infections for which standard treatments are not available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Influenza virus receptors in the human airway
Shinya, K., Ebina, M., Yamada, S., Ono, M., Kasai, N., & Kawaoka, Y. (2006) · Nature · doi:10.1038/440435a · Cited by 1,398
Time Lines of Infection and Disease in Human Influenza: A Review of Volunteer Challenge Studies
Carrat, F., Vergu, E., Ferguson, N. M., Lemaitre, M., Cauchemez, S., Leach, S., & Valleron, A.-J. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwm375 · Cited by 1,133
Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Furuta, Y., Gowen, B. B., Takahashi, K., Shiraki, K., Smee, D. F., & Barnard, D. L. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.015 · Cited by 1,072
Self-citationFavipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase
FURUTA, Y., KOMENO, T., & NAKAMURA, T. (2017) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.93.027 · Cited by 1,070
Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents
Hayden, F. G., Sugaya, N., Hirotsu, N., Lee, N., de Jong, M. D., Hurt, A. C., Ishida, T., Sekino, H., Yamada, K., Portsmouth, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716197 · Cited by 925
Resistant influenza A viruses in children treated with oseltamivir: descriptive study
Kiso, M., Mitamura, K., Sakai-Tagawa, Y., Shiraishi, K., Kawakami, C., Kimura, K., Hayden, F. G., Sugaya, N., & Kawaoka, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16934-1 · Cited by 786
Rates of spontaneous mutation among RNA viruses.
Drake, J. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.9.4171 · Cited by 712
Oral oseltamivir treatment of influenza in children
WHITLEY, R. J., HAYDEN, F. G., REISINGER, K. S., YOUNG, N., DUTKOWSKI, R., IPE, D., MILLS, R. G., & WARD, P. (2001) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200102000-00002 · Cited by 711
Guillot, L., Le Goffic, R., Bloch, S., Escriou, N., Akira, S., Chignard, M., & Si-Tahar, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410592200 · Cited by 689 · cited 1×
“TNF-α production is induced through recognition of the singlestrand RNA or double-strand RNA of the influenza virus genome by Toll-like receptor-7/8 (Yang & Chen, 2012) or 3 (Diebold et al., 2003; Guillot et al., 2005; Poux et al., 2019; Wong et al., 2009), respectively, in infected cells.”
Epidemiology of Human Infections with Avian Influenza A(H7N9) Virus in China
Li, Q., Zhou, L., Zhou, M., Chen, Z., Li, F., Wu, H., Xiang, N., Chen, E., Tang, F., Wang, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304617 · Cited by 688
Viral infection switches non-plasmacytoid dendritic cells into high interferon producers
Diebold, S. S., Montoya, M., Unger, H., Alexopoulou, L., Roy, P., Haswell, L. E., Al-Shamkhani, A., Flavell, R., Borrow, P., & Sousa, C. R. E. (2003) · Nature · doi:10.1038/nature01783 · Cited by 582
International guidelines for the selection of lung transplant candidates
Maurer, J. R., Frost, A. E., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · Transplantation · doi:10.1097/00007890-199810150-00033 · Cited by 562
Mechanism of Action of T-705 against Influenza Virus
Furuta, Y., Takahashi, K., Kuno-Maekawa, M., Sangawa, H., Uehara, S., Kozaki, K., Nomura, N., Egawa, H., & Shiraki, K. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.981-986.2005 · Cited by 546
Self-citationInfections With Oseltamivir-Resistant Influenza A(H1N1) Virus in the United States
Dharan, N. J. (2009) · JAMA · doi:10.1001/jama.2009.294 · Cited by 527
In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705
Furuta, Y., Takahashi, K., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., Watanabe, Y., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.977-981.2002 · Cited by 501
Self-citationOestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., & Günther, S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.02.014 · Cited by 493
Sissoko, D., Laouenan, C., Folkesson, E., M’Lebing, A.-B., Beavogui, A.-H., Baize, S., Camara, A.-M., Maes, P., Shepherd, S., Danel, C., et al. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1001967 · Cited by 478
Beis, I., & Newsholme, E. A. (1975) · Biochemical Journal · doi:10.1042/bj1520023 · Cited by 476
T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections
Furuta, Y., Takahashi, K., Shiraki, K., Sakamoto, K., Smee, D. F., Barnard, D. L., Gowen, B. B., Julander, J. G., & Morrey, J. D. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.02.198 · Cited by 471
Self-citationOmoto, S., Speranzini, V., Hashimoto, T., Noshi, T., Yamaguchi, H., Kawai, M., Kawaguchi, K., Uehara, T., Shishido, T., Naito, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27890-4 · Cited by 446
Smith, E. C., Blanc, H., Vignuzzi, M., & Denison, M. R. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003565 · Cited by 444
Favipiravir as a potential countermeasure against neglected and emerging RNA viruses
Delang, L., Abdelnabi, R., & Neyts, J. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2018.03.003 · Cited by 388
Kuhar, D. T., Henderson, D. K., Struble, K. A., Heneine, W., Thomas, V., Cheever, L. W., Gomaa, A., Panlilio, A. L., & US Public Health Service Working Group (2013) · Infection Control & Hospital Epidemiology · doi:10.1086/672271 · Cited by 377
Mechanism of action and selectivity of acyclovir
Elion, G. B. (1982) · The American Journal of Medicine · doi:10.1016/0002-9343(82)90055-9 · Cited by 370
Oseltamivir-Resistant Influenza Virus A (H1N1), Europe, 2007–08 Season
Meijer, A., Lackenby, A., Hungnes, O., Lina, B., van der Werf, S., Schweiger, B., Opp, M., Paget, J., van de Kassteele, J., Hay, A. J., et al. (2009) · Emerging infectious diseases · doi:10.3201/eid1504.081280 · Cited by 362
Toward a Comprehensive Phylogeny for Mammalian and Avian Herpesviruses
McGeoch, D. J., Dolan, A., & Ralph, A. C. (2000) · Journal of Virology · doi:10.1128/jvi.74.22.10401-10406.2000 · Cited by 331
The mechanism of resistance to favipiravir in influenza
Goldhill, D. H., te Velthuis, A. J. W., Fletcher, R. A., Langat, P., Zambon, M., Lackenby, A., & Barclay, W. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1811345115 · Cited by 298
Hurt, A. C., Ernest, J., Deng, Y.-M., Iannello, P., Besselaar, T. G., Birch, C., Buchy, P., Chittaganpitch, M., Chiu, S.-C., Dwyer, D., et al. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.03.003 · Cited by 277
Lai, S., Qin, Y., Cowling, B. J., Ren, X., Wardrop, N. A., Gilbert, M., Tsang, T. K., Wu, P., Feng, L., Jiang, H., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00153-5 · Cited by 276
Memoli, M. J., Athota, R., Reed, S., Czajkowski, L., Bristol, T., Proudfoot, K., Hagey, R., Voell, J., Fiorentino, C., Ademposi, A., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit725 · Cited by 274
Jin, Z., Smith, L. K., Rajwanshi, V. K., Kim, B., & Deval, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068347 · Cited by 268
Delang, L., Segura Guerrero, N., Tas, A., Quérat, G., Pastorino, B., Froeyen, M., Dallmeier, K., Jochmans, D., Herdewijn, P., Bello, F., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku209 · Cited by 232
Smither, S. J., Eastaugh, L. S., Steward, J. A., Nelson, M., Lenk, R. P., & Lever, M. S. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.012 · Cited by 228
T-705 (favipiravir) activity against lethal H5N1 influenza A viruses
Kiso, M., Takahashi, K., Sakai-Tagawa, Y., Shinya, K., Sakabe, S., Le, Q. M., Ozawa, M., Furuta, Y., & Kawaoka, Y. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909603107 · Cited by 207
Uehara, T., Hayden, F. G., Kawaguchi, K., Omoto, S., Hurt, A. C., De Jong, M. D., Hirotsu, N., Sugaya, N., Lee, N., Baba, K., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz244 · Cited by 191
Maurer, J., Frost, A., Estenne, M., Higenbottam, T., & Glanville, A. R. (1998) · PubMed · Cited by 187
Oestereich, L., Rieger, T., Neumann, M., Bernreuther, C., Lehmann, M., Krasemann, S., Wurr, S., Emmerich, P., de Lamballerie, X., Ölschläger, S., et al. (2014) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0002804 · Cited by 182
Tani, H., Fukuma, A., Fukushi, S., Taniguchi, S., Yoshikawa, T., Iwata-Yoshikawa, N., Sato, Y., Suzuki, T., Nagata, N., Hasegawa, H., et al. (2016) · mSphere · doi:10.1128/msphere.00061-15 · Cited by 170
Antiviral treatment of argentine hemorrhagic fever
Enria, D. A., & Maiztegui, J. I. (1994) · Antiviral Research · doi:10.1016/0166-3542(94)90030-2 · Cited by 161
Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice
Sidwell, R. W., Barnard, D. L., Day, C. W., Smee, D. F., Bailey, K. W., Wong, M., Morrey, J. D., & Furuta, Y. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01051-06 · Cited by 161
Wang, Y., Fan, G., Salam, A., Horby, P., Hayden, F. G., Chen, C., Pan, J., Zheng, J., Lu, B., Guo, L., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz656 · Cited by 158
Vignuzzi, M., Stone, J. K., & Andino, R. (2004) · Virus Research · doi:10.1016/j.virusres.2004.11.007 · Cited by 154
Bai, C., Mu, J., Kargbo, D., Song, Y., Niu, W., Nie, W., Kanu, A., Liu, W., Wang, Y., Dafae, F. M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw571 · Cited by 153
Favipiravir elicits antiviral mutagenesis during virus replication in vivo
Arias, A., Thorne, L., & Goodfellow, I. (2014) · eLife · doi:10.7554/elife.03679 · Cited by 150
Safronetz, D., Rosenke, K., Westover, J. B., Martellaro, C., Okumura, A., Furuta, Y., Geisbert, J. B., Saturday, G. A., Komeno, T., Geisbert, T. W., et al. (2015) · Scientific Reports · doi:10.1038/srep14775 · Cited by 141
Activation of toll-like receptor signaling pathway for protection against influenza virus infection
Wong, J. P., Christopher, M. E., Viswanathan, S., Karpoff, N. E. C., Dai, X., Das, D., Sun, L., Wang, M., & Salazar, A. Μ. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.01.048 · Cited by 135
Safronetz, D., Falzarano, D., Scott, D. P., Furuta, Y., Feldmann, H., & Gowen, B. B. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00886-13 · Cited by 121
Generation and characterization of influenza A viruses with altered polymerase fidelity
Cheung, P. P., Watson, S. J., Choy, K.-T., Sia, S. F., Wong, D., Poon, L. L. M., Kellam, P., Guan, Y., Peiris, M. J. S., & Yen, H. (2014) · Nature Communications · doi:10.1038/ncomms5794 · Cited by 115
Antipyretic activity of cinnamyl derivatives and related compounds in influenza virus-infected mice
KUROKAWA, M., Kumeda, C. A., Yamamura, J., Kamiyama, T., & Shiraki, K. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00121-6 · Cited by 113
Self-citationScharton, D., Bailey, K. W., Vest, Z. G., Westover, J. B., Kumaki, Y., Wettere, A. J. V., Furuta, Y., & Gowen, B. B. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.01.016 · Cited by 111
Caroline, A. L., Powell, D. S., Bethel, L. M., Oury, T. D., Reed, D. S., & Hartman, A. L. (2014) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0002790 · Cited by 110
Mendenhall, M., Russell, A., Smee, D. F., Hall, J. O., Skirpstunas, R. T., Furuta, Y., & Gowen, B. B. (2011) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001342 · Cited by 108
Nasal and otologic effects of experimental influenza A virus infection
Doyle, W. J., Buchman, C. A., Skoner, D. P., Seroky, J. T., Hayden, F., & Fireman, P. (1994) · Annals of Otology, Rhinology & Laryngology · doi:10.1177/000348949410300111 · Cited by 108
Vanderlinden, E., Vrancken, B., Houdt, J. V., Rajwanshi, V. K., Gillemot, S., Andreï, G., Lemey, P., & Naesens, L. M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01156-16 · Cited by 108
Damjanovic, D., Divangahi, M., Kugathasan, K., Small, C.-L. N., Zganiacz, A., Brown, E. G., Hogaboam, C. M., Gauldie, J., & Xing, Z. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.09.003 · Cited by 106
Gowen, B. B., Westover, J. B., Miao, J., Wettere, A. J. V., Rigas, J. D., Hickerson, B. T., Jung, K., Li, R., Conrad, B. L., Nielson, S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.01942-16 · Cited by 106
Efficacy of favipiravir (T-705) in nonhuman primates infected with Ebola virus or Marburg virus
Bixler, S. L., Bocan, T. M. A., Wells, J., Wetzel, K. S., Tongeren, S. A. V., Dŏng, L., Garza, N. L., Donnelly, G., Cazares, L. H., Nuss, J. E., et al. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.021 · Cited by 100
In Vitroandin VivoActivities of T-705 and Oseltamivir against Influenza Virus
Takahashi, K., Furuta, Y., Fukuda, Y., Kuno, M., Kamiyama, T., Kozaki, K., Nomura, N., Egawa, H., Minami, S., & Shiraki, K. (2003) · Antiviral chemistry & chemotherapy · doi:10.1177/095632020301400502 · Cited by 97
Self-citationWheeler, L. J., Rajagopal, I., & Mathews, C. K. (2005) · DNA repair · doi:10.1016/j.dnarep.2005.09.003 · Cited by 93
Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis
Escribano-Romero, E., de Oya, N. J., Domingo, E., & Sáiz, J. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01400-17 · Cited by 82
Takashita, E., Ejima, M., Ogawa, R., et al. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2016.06.007 · Cited by 73
Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models
Gowen, B. B., Wong, M., Jung, K., Smee, D. F., Morrey, J. D., & Furuta, Y. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.10.015 · Cited by 71
Tsurita, M., Kurokawa, M., Imakita, M., Fukuda, Y., Watanabe, Y., & Shiraki, K. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29389-7 · Cited by 66
Self-citationAntiviral Drugs Against Alphaherpesvirus
Shiraki, K. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-7230-7_6 · Cited by 63
Self-citationCharacterization of the DNA polymerase gene of varicella-zoster viruses resistant to acyclovir
Kamiyama, T., Kurokawa, M., & Shiraki, K. (2001) · Journal of General Virology · doi:10.1099/0022-1317-82-11-2761 · Cited by 47
Self-citationKu, A., & Chan, L. (1999) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.1999.t01-1-00329.x · Cited by 46
Biochemical Characterization of Enzyme Fidelity of Influenza A Virus RNA Polymerase Complex
Aggarwal, S., Bradel-Tretheway, B., Takimoto, T., Dewhurst, S., & Kim, B. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010372 · Cited by 40
Kurokawa, M., Watanabe, W., Shimizu, T., Sawamura, R., & Shiraki, K. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.11.001 · Cited by 35
Self-citationTanaka, T., KAMIYAMA, T., Daikoku, T., Takahashi, K., NOMURA, N., Kurokawa, M., & Shiraki, K. (2017) · Acta Virologica · doi:10.4149/av_2017_01_48 · Cited by 31
Self-citationHama, Y., Kurokawa, M., Imakita, M., Yoshida, Y., Shimizu, T., Watanabe, W., & Shiraki, K. (2009) · Acta Virologica · doi:10.4149/av_2009_04_233 · Cited by 25
Self-citationPoux, C., Dondalska, A., Bergenstråhle, J., Pålsson, S. A., Contreras, V., Arasa, C., Järver, P., Albert, J., Busse, D. C., Grand, R. L., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02161 · Cited by 25
Acute and Delayed Deaths after West Nile Virus Infection, Texas, USA, 2002–2012
Philpott, D., Nolan, M. S., Evert, N., Mayes, B. C., Hesalroad, D., Fonken, E., & Murray, K. O. (2019) · Emerging infectious diseases · doi:10.3201/eid2502.181250 · Cited by 17
Cytokine-regulatory activity and therapeutic efficacy of cinnamyl derivatives in endotoxin shock
Kurokawa, M., Brown, J., Kagawa, Y., & Shiraki, K. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)02036-3 · Cited by 14
Self-citationCharacterization of susceptibility variants of poliovirus grown in the presence of favipiravir
Daikoku, T., Mizuguchi, M., Obita, T., Yokoyama, T., Yoshida, Y., Takemoto, M., & Shiraki, K. (2017) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2017.03.004 · Cited by 9
Self-citationA Comparative Study of Human TLR 7/8 Stimulatory Trimer Compositions in Influenza A Viral Genomes
Yang, C., & Chen, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030751 · Cited by 8
Cited by
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Uyeki, T. M., Hui, D. S., Zambon, M., Wentworth, D. E., & Monto, A. S. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00982-5 · Cited by 560
Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19
Majumder, J., & Minko, T. (2021) · The AAPS Journal · doi:10.1208/s12248-020-00532-2 · Cited by 505
Role of favipiravir in the treatment of COVID-19
Joshi, S., Parkar, J., Ansari, A., Vora, A., Talwar, D., Tiwaskar, M., Patil, S., & Barkate, H. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.069 · Cited by 462
Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract
Flerlage, T., Boyd, D. F., Meliopoulos, V., Thomas, P. G., & Schultz-Cherry, S. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00542-7 · Cited by 402
Metadata
- Authors
- Shiraki, K., & Daikoku, T.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-05
- Volume
- 209
- Pages
- 107512
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W3008666619
- Cited by
- 573
- References
- 75
- FWCI
- 64.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.